Medtronic agrees to buy Covidien in €32 billion deal
Company will also move its executive base to Ireland as it aims to cut tax rates abroad
Medtronic chairman and chief executive Omar Ishrak said the deal with Covidien would allow the company to make more investment in US technologies. Photograph: Brendan McDermid/Files/Reuters
US medical device maker Medtronic has agreed to buy Covidien Plc for $42.9 billion (€32 billion) in cash and stock and move its executive base to Ireland in the latest transaction aiming for lower corporate tax rates abroad.
While the deal will allow Medtronic to reduce its overall global tax burden, the Minneapolis-based company said it was driven by a complementary strategy with Covidien on medical technology rather than tax considerations.
“The real purpose of this, in the end, is strategic, both in the intermediate term and the long term,” Medtronic chief executive Omar Ishrak said in an interview after the deal was announced. “It is good for the US in that we will make more investment in US technologies, which previously we could not.”
Medtronic’s corporate tax rate, now at around 18 per cent, won’t change much, Mr Ishrak said.
The merger of Medtronic, the world’s largest stand-alone medical device maker, and Covidien, a maker of devices used in a range of surgical procedures, will create a close competitor in size to the medical device business of industry leader Johnson & Johnson Co.
It broadens Medtronic’s scope beyond its array of heart devices, spinal implants, insulin pumps and other products into areas such as weight-loss surgery and laparoscopic procedures. The expansion should allow it to better compete for business from hospitals, particularly in the United States where healthcare reform efforts and shrinking government reimbursement for medical procedures has kept pressure on device pricing.
The disparate businesses means there should not be significant antitrust concerns, industry analysts said.
“Beyond the financial rationale, the company expands dramatically, and it puts them in a whole bunch of areas they never were in before. It makes sense,” said Jefferies analyst Raj Denhoy.
Mr Denhoy estimated the deal would shave 2 to 3 percentage points off the company’s corporate tax rate, pointing to Covidien’s rate of 16 per cent.
The deal values each Covidien share at $93.22, paid for by $35.19 in cash and 0.956 Medtronic shares. The transaction represents a 29 per cent premium to Covidien’s closing stock price on Friday, Medtronic said.
The combination, which will leave Covidien shareholders owning about 30 per cent of the combined company, is expected to result in at least $850 million of annual pre-tax cost synergies by the end of fiscal year 2018. Medtronic said it would keep its operational headquarters in Minneapolis and pledged $10 billion in US technology investments over the next 10 years.
Acquisitions of companies aimed at lowering corporate tax rates, known as inversions, have historically been rare but are becoming more common.
Some US lawmakers are concerned that the deals erode government revenue by giving corporations another tax-avoiding loophole. Two bills in the US Congress and a White House proposal would make inversions harder to do, but neither has gained much traction. That could change if another major US company or two tried to conduct inversions, tax lawyers and analysts said last week.
Two recently attempted inversions failed, but only after they refocused political attention on the strategy. US-based Pfizer’s bid for rival British drugmaker AstraZeneca was rejected, while the proposed combination of US advertising firm Omnicom Group with France’s Publicis Groupe collapsed for non-tax-related reasons.
Democrats in Congress have called for new restrictions on these deals, with bills offered by Senator Carl Levin and his brother, Representative Sander Levin, both Michigan Democrats. President Barack Obama has a proposal similar to the Levins’. Republicans have expressed concern about inversions, but have not put forward legislation of their own.
Some lawmakers have said that anti-inversion curbs should be tackled as part of a comprehensive overhaul of the loophole-riddled US tax code, but this is a difficult project that Congress has not tackled since 1986.
Medtronic’s deal with Covidien is expected to close in the fourth quarter of 2014 or early 2015, Medtronic said.
Perella Weinberg Partners LP, Cleary Gottlieb Steen & Hamilton LLP and A & L Goodbody advised Medtronic, while Goldman Sachs & Co and Wachtell, Lipton, Rosen & Katz and Arthur Cox advised Covidien. Bank of America Merrill Lynch provided committed financing for the transaction.